| Patents for A61P 43 - Drugs for specific purposes, not provided for in groups (156,317) |
|---|
| 07/22/2004 | WO2003006002A9 Compositions and methods of administering tubulin binding agents for the treatment of ocular diseases |
| 07/22/2004 | WO2002101076A3 Methods for targeted expression of therapeutic nucleic acid |
| 07/22/2004 | WO2002099048A3 LIMKs AS MODIFIERS OF THE p53 PATHWAY AND METHODS OF USE |
| 07/22/2004 | WO2002096886A8 Pyrimidine derivatives |
| 07/22/2004 | WO2002088090A3 Pyrazole derived kinase inhibitors |
| 07/22/2004 | US20040143857 Erythropoietin analog-human serum albumin fusion |
| 07/22/2004 | US20040143115 e.g., 1-[2-Benzoxazol-2-ylaminomethyl)-piperidin-1-yl]-1-(2-methyl-5phenyl-thiazol4-yl)-methanone; used to treat disorders where an antagonist of a human orexin receptor is required |
| 07/22/2004 | US20040143095 for treating high body temperature, appetite dysfunction, congestive heart failure, vascular disease, stress and anxiety; angiogenesis inhibitors; genetic engineering |
| 07/22/2004 | US20040143020 Psychological and central nervous system disorders |
| 07/22/2004 | US20040143017 Methods of treating osteoarthritis with inducible nitric oxide synthase inhibitors |
| 07/22/2004 | US20040143010 Synergistic mixture with phosphodiesterase inhibitor; control concentration of cyclic guanosine monophosphate in penis |
| 07/22/2004 | US20040143006 Peroxisome proliferator activator; antidiabetic agents; insulin resistance; |
| 07/22/2004 | US20040143003 Cyclopropylindole derivatives as selective serotonin reuptake inhibitors |
| 07/22/2004 | US20040142999 Novel compounds and compositions as cathepsin inhibitors |
| 07/22/2004 | US20040142996 Peripherally-selective inhibitors of dopamine-beta-hydroxylase and method of their preparation |
| 07/22/2004 | US20040142993 Viricides |
| 07/22/2004 | US20040142990 Concentrating epothilone in culture; complexing; antiproliferative agents |
| 07/22/2004 | US20040142989 Viricides |
| 07/22/2004 | US20040142988 Bladder diseases; bone diosrders; central nerevous system diosrders |
| 07/22/2004 | US20040142982 Urea derivatives as integrin alpha 4 antagonists |
| 07/22/2004 | US20040142976 Modulation cytokine sensitive diseases, cellular adhesion molecules; Aids therapy; antihistamines; antiarthritic agents; bone disorders; malaria; cachexia; Crohn's disease |
| 07/22/2004 | US20040142967 Pain maintenance |
| 07/22/2004 | US20040142966 4-(phenyl-(piperidin-4yl)-amino)-benzamide derivatives and their use for the treatment of pain, anxiety or gastrointestinal disorders |
| 07/22/2004 | US20040142963 Cardiovascular disorders |
| 07/22/2004 | US20040142961 Utilization of substituted imidazo[1,2-a]-pyridine compounds in pharmaceutical formulations |
| 07/22/2004 | US20040142954 Antiinflammatory agents; antihistamines; Alzheimer's disease; anticholesterol agents; cardiovascular disorders; inflammatory bowel disorders; antitumor agents; antidiabetic agents; brain disorders; multiple sclerosis |
| 07/22/2004 | US20040142952 Triazoloquinazoline and pyrazolotriazolopyrimidine derivatives, medicinal compositions, adenosine a3 receptor affinity agents, ocular tension lowering agents, preparations for preventing and treating glaucoma and method of lowering ocular tension |
| 07/22/2004 | US20040142947 Pyrrolopyrimidines |
| 07/22/2004 | US20040142944 Compositions for nasal application |
| 07/22/2004 | US20040142935 Dihydroimidazo[4,5-e]indole and 7h-pyrrolo[3,2-f]quinoxaline derivatives as nicotinic acetylcholine receptor liqands and/or serotonergic ligands |
| 07/22/2004 | US20040142934 treatment of rheumatoid arthritis and/or pain; INHIBIT activity of VEGF receptor tyrosine kinase and VEGF-dependent cell proliferation |
| 07/22/2004 | US20040142932 treating diseases and conditions caused or exacerbated by unregulated p38 MAP Kinase activity |
| 07/22/2004 | US20040142927 Inhibitors of p38 |
| 07/22/2004 | US20040142925 Piperazine derivatives their preparation and uses in therapy |
| 07/22/2004 | US20040142919 Benzazepinone alpha vintegrin receptor antagonists |
| 07/22/2004 | US20040142901 Production of pancreatic islet cells and delivery of insulin |
| 07/22/2004 | US20040142886 use of vascular endothelial growth factor to enhance smooth muscle cell proliferation and to treat diseases associated with reduced smooth muscle cell proliferation |
| 07/22/2004 | US20040142882 Use of glycyrrhizin and its derivatives as RANTES inducers |
| 07/22/2004 | US20040142877 Ligands of the $g(a)v$g(b)6 integrin |
| 07/22/2004 | US20040142871 Osteoporosis treatment |
| 07/22/2004 | US20040142863 modified aggrecanases, nucleotides encoding such enzymes, and processes for producing these enzymes with improved stability; treatment of osteoarthritis |
| 07/22/2004 | US20040142851 by inducing the apoptosis according to a inhibition mechanism of the enzyme activities of proteasome |
| 07/22/2004 | US20040142417 Receptor proteins |
| 07/22/2004 | US20040142354 used to diagnose and/or treat a wide variety of liver and other disorders (cancer) and tracing hepatocyte lineage; genetic engineering |
| 07/22/2004 | US20040142342 Antibodies to non-functional P2X7 receptor diagnosis and treatment of cancers and other conditions |
| 07/22/2004 | US20040142317 Use of amino acid transporter atbo,+ as a delivery system for drugs and prodrugs |
| 07/22/2004 | US20040142043 spray-dried fine powder comprising an active protein and a saccharide such as mannitol or cyclodextrin having a particle diameter of 10 mu m or less uniformly dispersed in the matrix of a biodegradable polymer |
| 07/22/2004 | US20040141982 Use of genetically engineered antibodies to treat multiple myeloma |
| 07/22/2004 | US20040141973 IPG antagonists for the treatment of conditions involving mast cells, basophils and eosinophils |
| 07/22/2004 | US20040141967 Methods and compositions for treating macrophage-mediated diseases |
| 07/22/2004 | US20040141966 Inhibition of leukocyte adhesion |
| 07/22/2004 | US20040141945 novel material which combines cell-adhesive proteins such as collagen with GAG polymers to construct an environment similar to an extracellular matrix, capable of controlling differentiation and proliferation of cells |
| 07/22/2004 | US20040141917 Antibodies to truncated VEGF-D and uses thereof |
| 07/22/2004 | US20040141912 Administering medicinally-useful agent which is phospholipid scramblase (PLS)-dependent transported compound to cells, thereby causing selective transport of agent into cells |
| 07/22/2004 | CA2512002A1 Method of selecting novel immunosuppressant |
| 07/22/2004 | CA2511737A1 Body weight gain inhibitor |
| 07/21/2004 | EP1439226A2 A nucleic acid antisense sequence to a polynucleotide encoding a polypeptide having heparanese activity |
| 07/21/2004 | EP1439193A2 Antibody directed to polypeptide having heparanase activity |
| 07/21/2004 | EP1439190A1 Growth differentiation factor-5 |
| 07/21/2004 | EP1439178A1 HETEROCYCLIC COMPOUNDS, OXAZOLE DERIVATIVES, PROCESS FOR PREPARATION OF THE SAME AND USE THEREOF |
| 07/21/2004 | EP1439176A1 Pyrimidone compounds and pharmaceutical compositions containing the same |
| 07/21/2004 | EP1439175A1 Pyrimidine compound and medicinal composition thereof |
| 07/21/2004 | EP1439174A1 4-imidazolin-2-one compounds |
| 07/21/2004 | EP1439164A1 Novel phenylethanolamine compounds having beta2-acceptor excitatory function and their preparation method |
| 07/21/2004 | EP1438972A1 Remedy for ischemic heart failure |
| 07/21/2004 | EP1438968A1 Topical compositions containing at least one polypeptide hydrolase with an amidasic activity and /or compounds capable of modulating this activity |
| 07/21/2004 | EP1438966A2 Use of depsipeptide and congeners thereof as immunosuppressants for treating an infectious disease, an autoimmune disease, allergic reactions or a hyperproliferative skin disease |
| 07/21/2004 | EP1438964A1 Process for producing collagen production enhancers and use thereof |
| 07/21/2004 | EP1438962A1 DRUGS COMPRISING COMBINATION OF TRIAZASPIRO 5,5 U NDECANE DERIVATIVE WITH CYTOCHROME P450 ISOZYME 3A4 INHIBITOR AND/OR P−GLYCOPROTEIN INHIBITOR |
| 07/21/2004 | EP1438957A1 Benzothiophene formulations of a specific dosage |
| 07/21/2004 | EP1438434A2 Isolated nucleic acid molecules encoding a bacterial uracil transport protein and a bacterial uracil phosphoribosyl-transferase enzyme, cells transformed therewith and uses thereof |
| 07/21/2004 | EP1438431A2 Methods for diagnosing and treating heart disease |
| 07/21/2004 | EP1438412A2 Methods and compositions for inducing tumor-specific cytotoxicity |
| 07/21/2004 | EP1438410A2 Promoters to control cell differentiation |
| 07/21/2004 | EP1438407A1 Obesity related genes expressed at least in the hypotalamus, liver or pancreas |
| 07/21/2004 | EP1438405A1 Use of a double-stranded ribonucleic acid for specifically inhibiting the expression of a given target gene |
| 07/21/2004 | EP1438404A2 Inhibition of specific histone deacetylase isoforms |
| 07/21/2004 | EP1438389A2 Methods for diagnosing and treating diseases and conditions of the heart or digestive system, and cancer |
| 07/21/2004 | EP1438378A1 Cholesterol lowering structured lipids with omega 6 pufa |
| 07/21/2004 | EP1438339A2 Human antibodies that have mn binding and cell adhesion-neutralizing activity |
| 07/21/2004 | EP1438335A1 Ferroportin-1 mutant |
| 07/21/2004 | EP1438321A1 Modified l-nucleic acid |
| 07/21/2004 | EP1438320A1 Novel hydroxyalkyl indolocarbazole derivatives, preparation method and pharmaceutical compositions containing same |
| 07/21/2004 | EP1438319A1 Derivatives of etoposide and analogs, and pharmaceutical compositions containing them |
| 07/21/2004 | EP1438316A1 Phosphonic acid compounds as inhibitors of serine proteases |
| 07/21/2004 | EP1438313A1 Bicyclic oxopyridine and oxopyrimidine derivatives |
| 07/21/2004 | EP1438310A1 Beta-carbolin derivatives as ptp-inhibitors |
| 07/21/2004 | EP1438307A2 Derivatives of 4-(thio- or selenoxanthene-9-ylidene)-piperidine or acridine and its use as a selective 5-ht2b receptor antagonist |
| 07/21/2004 | EP1438304A1 Novel substituted 4-phenyl-4- 1h-imidazol-2-yl]-piperidine derivatives and their use as selective non-peptide delta opioid agonists |
| 07/21/2004 | EP1438302A1 New sulfonamide derivatives as d3-receptor agonists |
| 07/21/2004 | EP1438298A1 Piperazine derivatives with ccr1 receptor antagonist activity |
| 07/21/2004 | EP1438297A1 Mibefradil-based compounds as calcium channel blockers useful in the treatment of hypertension and angina |
| 07/21/2004 | EP1438296A2 1h-imidazole derivatives having cb1 agonistic, cb1 partial agonistic or cb1- antagonistic activity |
| 07/21/2004 | EP1438295A2 Azole derivatives and pharmaceutical compositions containing them |
| 07/21/2004 | EP1438293A2 Substituted pyrazolyl benzenesulfamide compounds for the treatment of inflammation |
| 07/21/2004 | EP1438292A1 6-membered heterocyclic compounds useful for selective inhibition of the coagulation cascade |
| 07/21/2004 | EP1438290A1 Cyclohept b!indole derivatives as spla2 inhibitors |
| 07/21/2004 | EP1438289A1 Indole derivatives as cox ii inhibitors |
| 07/21/2004 | EP1438288A1 Substituted thioacetamides |
| 07/21/2004 | EP1438285A1 Acetic acid derivatives |